F

or India’s biggest drug makers, the Trump administration offers a mix of promise and peril.

On one hand, these companies supply many lower-cost generics to the United States, a key advantage as President Trump accuses most brand-name drug makers of “getting away with murder” when it comes to pricing. But Indian drug makers also fret the Trump administration will place them at a disadvantage with any policies that favor domestic jobs stemming from products made in the US.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • And such quality issues continue, as evidenced in a letter dated this month. [Warning Letter 320-17-28] That will be a hard slog:
    “These findings indicate that your quality unit is not exercising its responsibilities.
    In your response, you admitted that a “gap exist[ed] in the Quality Assurance department” concerning document control. “

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.